Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. He highlights progress in developing treatments for autoimmune diseases and anticipates milestones for the year ahead.
Copyright 2024 – Finance News Network
30 Nov 2021 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow talks about the recent presentation of data from the CHM 1101 (Chlorotoxin CAR T) Phase 1 clinical trial in glioblastoma patients.
27 Feb 2020 - NetLinkz Limited (ASX:NET) Executive Chairman and CEO, James Tsiolis talks about the significance of the company's agreement to provides its Virtual Secure Network to a World Bank-sponsored initiative to improve water sanitation services in selected areas of the Deyang Municipality of Sichuan Province.
29 07 2024 - Gregory Hall - CEO & Managing Director - Alligator Energy (ASX:AGE) is an Australian, ASX-listed, exploration company focused on uranium and energy related minerals, principally cobalt-nickel. Alligator’s Directors have significant experience in the exploration, development and operations of both uranium and nickel projects (both laterites and sulphides).
27 May 2024 - Jonathan Belz, founder of BFA Global connects Australian and Asian family offices with top global investment opportunities in venture capital, private equity, and technology. He shares insights into the future of alternative assets and investment strategies.
02 Oct 2019 - Noxopharm Limited (ASX:NOX) Founder and Executive Chairman, Dr Graham Kelly, discusses early results on the use of Noxopharm's lead drug candidate, Veyonda, for the treatment of prostate cancer.
18 Nov 2024 - Empire Energy Group Limited (ASX:EEG) has commenced drilling for its Carpentaria Pilot Project after receiving environmental clearance. The initiative aims to deliver much-needed gas to the Northern Territory and east coast markets, supported by local and federal government strategies.
22 Nov 2021 - Arovella Therapeutics Limited (ASX:ALA) CEO & Managing Director Dr Michael Baker provides an update on the company's invariant Natural Killer T (iNKT) cell platform and its oral spray delivery technology to treat cancer and conditions that affect the central nervous system.
03 Jun 2020 - Cyclopharm (ASX:CYC) Managing Director and CEO James McBrayer provides an update on US FDA progress with Technegas, approval in Russia and potential use of Technegas in the diagnosis and management of COVID-19.
